On August 29, Tianjin Pharmaceutical Co., Ltd. issued an announcement stating that the company recently received the "Approval Notice for Marketing Application of Difluprednisolone Chemical Raw Material" issued by the National Medical Products Administration.   

Difluprednisolone is a topical corticosteroid that can inhibit inflammatory responses caused by various irritants. Currently, it is mainly available as eye drops, primarily used to treat inflammation and pain associated with eye surgery. The company's difluprednisolone eye drops received a Drug Registration Certificate in August 2025. This approval of the active pharmaceutical ingredient (API) will further enrich the company's product portfolio, fully leverage its integrated API and formulation advantages, and help expand its business scope.

As a steadfast practitioner of the integrated API and formulation strategy in China's pharmaceutical industry, Tianjin Pharmaceutical Group has cultivated its expertise in the field for many years, extending its API advantages to the formulation sector. By integrating upstream and downstream industrial chains, it promotes the synergistic development of its integrated "API + formulation" strategy. The approval of difluprednisolone eye drops and its API demonstrates the company's integrated API and formulation advantages.

Articles: Board Office of Tianjin Pharmaceutical Group Co., Ltd., China Securities Journal (China Securities Network)